ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PDEX / earnings
STIM (28) KTWO (56) UTMD (62) PROF (40) ⌘ Pro Terminal →

Pro-Dex Inc. (PDEX) Next Earnings Date & Expected ±9.4% Move

$57.65 -0.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $57.45

Pro-Dex Inc. (PDEX) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $186.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PDEX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PDEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Pro-Dex Inc. (NASDAQ: PDEX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $57.65 (-0.88% 1D, market cap $186.1M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, PDEX ranks #220 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PDEX compare to STIM and KTWO in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), PDEX carries a Roarable D+ (54/100 RQD), trailing P/E of 22.2x, gross margin of 29.3%, and ROIC of 23.2%. By comparison, STIM (Neuronetics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $171.4M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PDEX?
▼

Per PDEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000788920), Pro-Dex Inc. generated $66.6M in revenue (+23.7% YoY), $9.0M in net income, and -$2.9M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $57.45 (-0.35%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+
Cash (11)Whales (6)SEC (16)Macro (11)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
$81 Bull$57 Base$44 Bear
📬 FREE PDEX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PDEX)Realized 20D OHLCV Swing Band: ±9.4%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY PDEX SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (30% of score)

Altman Z-Score 9.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 29.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$62.27-4.6% Next Q
Q2 (-2Q)
59
Grade C$59.40+4.8% Next Q
Q3 (-1Q)
57
Grade C$62.27-7.4% Next Q
Current
54
Grade D+$57.65-0.7% Hist 90D α
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PDEX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PDEX currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($64.51) and Max Pain ($60.53) forces dealer call-delta covering toward $80.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PDEX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PDEX Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 28, 2026 (~54 DAYS)

Historical OHLCV Volatility ±9.4% Swing Band

±$5.42 Expected Swing
$52.23 (-9.4%)Spot $57.65$63.07 (+9.4%)
MODEL EARNINGS SETUP GAUGE

PDEX Quantitative Pre-Earnings Setup: 54/100

Trailing EPS: $2.78 • YoY Revenue Growth: 23.7%

Model Bullish Setup (54/100)Model Risk Weight (46/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-06-30$66.6M$9.0M-$2.9M29.3%
FY 20242024-06-30$53.8M$2.1M$6.2M27%
FY 20232023-06-30$46.1M$7.1M$5.5M29.3%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PDEX)

  • ✓Walkthrough of PDEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PDEX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.53%🛡️ HOLDING TREND SUPPORT
2026-11-03O $61.60H $61.60L $57.65C $57.65VOL 38.5K
RES: $81.98SUP: $56.53SMA50: $64.51SMA200: $56.74
$79.52$69.09$58.66$48.23$37.80RES $81.98SUP $56.53$57.652026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PDEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PDEX Butterfly Map → + Track PDEX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
15.9%/yr Implied 5Y Growth

vs. +23.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PDEX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PDEX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PDEX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PDEX)

Health Care Rank #220 of 1015 ⚔️ STIM vs PDEX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PDEX vs. STIM, KTWO, UTMD, PROF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pro-Dex Inc. (PDEX) ranks #220 by composite RQD confidence (54/100, grade D+) and #582 by equity capitalization ($186.1M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with PDEX at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PDEX ACTIVE
Pro-Dex Inc.
D+ 54/100 22.2x 29.3% 23.2% -0.88% $186.1M Benchmark Subject
STIM
Neuronetics Inc.
E 28/100 — 48.5% -35.0% -8.44% $171.4M /stim-vs-pdex →
KTWO
K2 Capital Acquisition Corporation Class A Ordinary Share
D+ 56/100 — — — +0.20% $202.2M /ktwo-vs-pdex →
UTMD
Utah Medical Products Inc.
C 62/100 — 57.1% 26.9% +3.64% $216.7M /utmd-vs-pdex →
PROF
Profound Medical Corp.
D- 40/100 — 70.8% -35.0% +2.44% $240.0M /prof-vs-pdex →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000788920 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Pro-Dex Inc. (PDEX) reported GAAP revenue of $66.6M (+23.7% vs. FY2024 revenue of $53.8M , and +44.5% cumulative change since FY2023) , GAAP net income of $9.0M, operating cash flow of -$1.7M, and free cash flow of -$2.9M (-147.0% YoY). On the balance sheet, PDEX closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: 9.08, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $66.6M $9.0M -$1.7M -$2.9M $62.3M —
FY2024 (FY) 2024-06-30 $53.8M $2.1M $6.2M $6.2M $60.4M —
FY2023 (FY) 2023-06-30 $46.1M $7.1M $5.5M $5.5M — —

3. PDEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PDEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pro-Dex Inc. (NASDAQ: PDEX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $57.65 (-0.88% 1D, market cap $186.1M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, PDEX ranks #220 in composite RQD confidence.

How does PDEX compare to STIM and KTWO in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PDEX carries a Roarable D+ (54/100 RQD), trailing P/E of 22.2x, gross margin of 29.3%, and ROIC of 23.2%. By comparison, STIM (Neuronetics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $171.4M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PDEX?

Per PDEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000788920), Pro-Dex Inc. generated $66.6M in revenue (+23.7% YoY), $9.0M in net income, and -$2.9M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PDEX trading relative to its 50-day, 200-day, and 52-week technical levels?

PDEX last traded at $57.65 (-0.88% on volume of 63,158 shares), positioning the stock -10.63% below its 50-day simple moving average ($64.51) and +1.60% above its 200-day simple moving average ($56.74). Across its 52-week range of $28.81 to $77.00, PDEX sits at the 59.8% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($52.23 to $63.07).

Direct Sub-Reports: PDEX RQD Cockpit PDEX 12M Forecast PDEX Earnings & Move PDEX Dividends & DRIP PDEX Insiders & 13F PDEX Whale Options PDEX Profit Sankey PDEX News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

PDEX — Pro-Dex Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pro-Dex Inc. (PDEX) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $57.65 (-0.88% 1D, market capitalization $186.1M).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 23.2%, gross margin of 29.3%, operating margin of 16.1%, and free cash flow yield of -1.47%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.08, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pro-Dex Inc. (PDEX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile describes the company as having a market capitalization of $0.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Pro-Dex Inc. (PDEX) reported $66.6M in annual revenue (up from $53.8M in FY2024, +23.7% YoY) and $9.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.1M revenue, $7.1M net income) through FY2025, PDEX scaled operating cash flow to -$1.7M and free cash flow to -$2.9M, backed by $62.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 54/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -1.47% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $28.81 – $77.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 22.2x trailing P/E and 16.5x EV/EBITDA against 16.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), PDEX carries a macro regime beta of 1.00 and gross margin of 29.3%.

  • Key Question #1: Can PDEX sustain or expand its 16.1% operating margin and 23.2% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $66.6M and free cash flow of -$2.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PDEX's 18.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PDEX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pro-Dex Inc. (PDEX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PDEX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PDEX Bull vs. Bear Conversation Board — What's Your Call at $57.65?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PDEX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PDEX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $72.12 (+24.0%)
📌 Pinned Debate

Forensic balance sheet scores 16 of 20 with Altman Z 9.08 and Debt/Equity 0.5, and FY 2025 operating income of $10.7M sits above net in

Here is why I am bullish on PDEX here at $58.16: Forensic balance sheet scores 16 of 20 with Altman Z 9.08 and Debt/Equity 0.5, and FY 2025 operating income of $10.7M sits above net income of $9.0M.. Compare PDEX's 16.1% operating margin and 23.2% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $55.25 are getting bought.

SectorRotator 🐂 BULL

@CashFlowKing Agree on the RQD 54/100 quality, though with 1.0 beta I'm scaling in with half-size at $58.16 and keeping dry powder in case we test $54.09.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $45.95 (-21.0%)
Spot @ $58.16

FY 2025 free cash flow turned negative at -$2.9M and FCF yield is -1.47%, with whale and insider pillars scoring 9 and 10 of 20.

FY 2025 free cash flow turned negative at -$2.9M and FCF yield is -1.47%, with whale and insider pillars scoring 9 and 10 of 20.. Look at the math on PDEX: paying 22.2x trailing P/E for 23.2% ROIC and 16.1% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $51.18 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%